The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.
Patients hospitalized for ADHF secondary to fluid overload and who are experiencing an inadequate response to IVB furosemide and require additional diuresis will be enrolled. Patients will be randomized to one of two treatment arms: the addition of oral metolazone to continued IVB furosemide versus transition from IVB to CI furosemide. A suggested algorithm for initial dosing and titration of these two diuretic strategies will be provided. Baseline and daily data collection will include various efficacy and safety endpoints including daily net urine output and weight, patient and physician global assessment scale, length of stay, 30-day death or rehospitalization, vital signs, electrolytes, and renal function. Clinically meaningful efficacy and safety endpoints will be compared.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
11
Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
UNC_Chapel Hill
Chapel Hill, North Carolina, United States
Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)
Net fluid output = fluid output during 24-48 hours after randomization - fluid intake during 24-48 hours after randomization. A negative value means that daily fluid intake was less than the daily fluid output.
Time frame: 24-48 hours
Daily Net Fluid Output on Days 1, 3, and 4
Daily net fluid output = daily fluid output - daily intake. A negative value means that daily fluid intake was less than the daily fluid output.
Time frame: 0-24, 48-72, 72-96 hrs
Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)
Time frame: 0-24, 24-48, 48-72, 72-96 hrs
Daily Weight
Time frame: Baseline (Dry), Baseline, 0-24, 24-48, 48-72, 72-96 hrs
Patient Global Assessment Scale
Scale range: 1-5 Which of the following best describes your overall health state today? 1. = markedly worse 2. = worse 3. = neither better nor worse 4. = better 5. = markedly better
Time frame: Baseline, 24, 48, 72, 96 hrs
Physician Global Assessment Scale
Scale range: 1-5 Which of the following best describes the patient's overall health state today? 1. = markedly worse 2. = worse 3. = neither better nor worse 4. = better 5. = markedly better
Time frame: Baseline, 24, 48, 72, 96 hours
Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure)
Patients will be considered a treatment failure if they require additional diuretic (including crossover to the alternative study arm) or require IV vasoactive drug therapy (e.g. vasodilators including nitroglycerin or inotropes) as deemed appropriate/necessary by their medical team.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 0-96 hours
Time to Return to Baseline Weight
Time frame: 0-96 hours
Length of Hospitalization
Time frame: Assessed till hospital discharge, an average of 1 week (longest 29 days)
30-day All-cause Mortality
Time frame: 30 days
Rehospitalization at 30 Days
Time frame: 30 days
Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic
Time frame: 30 days
Blood Urea Nitrogen (BUN)
Time frame: Baseline, 24, 48, 72, 96 hours